Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHR160 is an investigational herbal inhaler spray developed by Baqiyatallah Medical Sciences University in Tehran, Iran, for the treatment of COVID-19 (SARS-CoV-2 infection). It is a multi-component botanical formulation extracted from seven plant species via steam distillation. The formulation contains a combination of active constituents including cineole (sineol), menthol, crocin, safranal, alpha-thujone, and various fatty acids such as oleic, linoleic, and linolenic acids. Rooted in Iranian Traditional Medicine, PHR160 is designed to address pulmonary involvement and symptoms in hospitalized patients. Each puff of the spray delivers 160 micrograms of the active substance. The drug has been evaluated in multi-center, randomized, double-blind clinical trials to assess its safety and efficacy in improving clinical outcomes for patients with pulmonary complications from COVID-19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PHR160 (Baqiyatallah University of Medical Sciences).